Ziopharm Oncology Other Current Liabilities

As of the most recent data (June 2026), ZIOP shows a other current liabilities of $130K. That compares with $270K in the prior-year period — down 50.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZIOP's other current liabilities is now $130K (was $270K) — a 50.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ziopharm Oncology is outperforming or lagging.

Tracking ZIOP's other current liabilities over time shows whether Ziopharm Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $130K That compares with $270K in the prior-year period — down 50.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Ziopharm Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $130K) with ownership activity and broader fundamentals.

Ziopharm Oncology's other current liabilities is $130K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.